Scholarlink

<p>Studies have shown that sphingomyelin (SM) supplementation can improve lipid metabolism, regulate intestinal microbiota, and attenuate chronic metabolic diseases in obese mice or mice fed a high-fat diet (HFD). Therefore, we hypothesized that dietary SM supplementation benefits mice with disturbed lipid metabolism. To test our hypothesis, we conducted a meta-analysis to evaluate the effects of dietary SM supplementation on physiological indicators such as body weight, hepatic, and blood parameters in normal C57BL/6 mice or obese model mice fed a HFD. Multiple databases including PubMed, Web of Science, Cochrane Library, Embase, and China National Knowledge Infrastructure were searched to identify randomized controlled trials that were set to investigate the effects of dietary SM supplementation in obese mice fed a HFD. The search was limited to studies published between January 1, 2000, and September 30, 2024. The Cochrane bias risk assessment tool was used to evaluate and cross-check the literature quality of the included animal experiments. The meta-analysis was performed using Review Manager 5.4 software. A total of 14 articles were included in this study, and the experimental mice were divided into two categories with a total of 612 animals. One study&#xa0;included normal C57BL/6 mice fed a HFD, and the other&#xa0;studies used&#xa0;obese model mice. Compared with the control group, dietary SM supplementation did not affect blood SM and total phospholipids content in obese mice fed a HFD. The addition of dietary SM supplementation significantly reduced the levels of hepatic total lipids, triglyceride, total cholesterol (TC) and liver weight in both normal and obese&#xa0;mice, lowered intestinal cholesterol absorption, and substantially increased fecal lipid profile including total lipids, and TC levels&#xa0;in normal mice. Furthermore, dietary SM improved inflammatory cytokine levels and glycemic profile. The findings of this meta-analysis indicate that SM supplementation in the diet may have a protective effect against impaired lipid metabolism in obese mice. Basic research and further clinical trials are needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The protective effect of dietary sphingomyelin supplementation against impaired lipid metabolism in obese mice: a systematic review and meta-analysis of randomized controlled trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月16日

查看全文
  • Xiao-Yan Qin,
  • Jie Pan,
  • Yi-Na Liu,
  • Hui-Min Luo,
  • Fang Yang

摘要

Studies have shown that sphingomyelin (SM) supplementation can improve lipid metabolism, regulate intestinal microbiota, and attenuate chronic metabolic diseases in obese mice or mice fed a high-fat diet (HFD). Therefore, we hypothesized that dietary SM supplementation benefits mice with disturbed lipid metabolism. To test our hypothesis, we conducted a meta-analysis to evaluate the effects of dietary SM supplementation on physiological indicators such as body weight, hepatic, and blood parameters in normal C57BL/6 mice or obese model mice fed a HFD. Multiple databases including PubMed, Web of Science, Cochrane Library, Embase, and China National Knowledge Infrastructure were searched to identify randomized controlled trials that were set to investigate the effects of dietary SM supplementation in obese mice fed a HFD. The search was limited to studies published between January 1, 2000, and September 30, 2024. The Cochrane bias risk assessment tool was used to evaluate and cross-check the literature quality of the included animal experiments. The meta-analysis was performed using Review Manager 5.4 software. A total of 14 articles were included in this study, and the experimental mice were divided into two categories with a total of 612 animals. One study included normal C57BL/6 mice fed a HFD, and the other studies used obese model mice. Compared with the control group, dietary SM supplementation did not affect blood SM and total phospholipids content in obese mice fed a HFD. The addition of dietary SM supplementation significantly reduced the levels of hepatic total lipids, triglyceride, total cholesterol (TC) and liver weight in both normal and obese mice, lowered intestinal cholesterol absorption, and substantially increased fecal lipid profile including total lipids, and TC levels in normal mice. Furthermore, dietary SM improved inflammatory cytokine levels and glycemic profile. The findings of this meta-analysis indicate that SM supplementation in the diet may have a protective effect against impaired lipid metabolism in obese mice. Basic research and further clinical trials are needed.